Genome-level determination of plasmodium falciparum blood-stage targets of malarial clinical immunity in the peruvian amazon

Journal of Infectious Diseases

Volumn 211, Issue 8, 2015, Pages 1342-1351

  Torres, Katherine J ^a   Castrillon, Carlos E ^a   Moss, Eli L ^c   Saito, Mayuko ^a,d   Tenorio, Roy ^a,b   Molina, Douglas M ^e   Davies, Huw ^e   Neafsey, Daniel E ^c   Felgner, Philip ^e   Vinetz, Joseph M ^a,b,d   Gamboa, Dionicia ^a,b  

^a Laboratorio de Malaria   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

geographic medicine; immunology; malaria; systems biology

Indexed keywords

IMMUNOGLOBULIN G; PARASITE ANTIGEN; MALARIA VACCINE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN RECOGNITION; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; GENE IDENTIFICATION; GENETIC CODE; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; MALARIA FALCIPARUM; MALE; MICROARRAY ANALYSIS; MOLECULAR RECOGNITION; NONHUMAN; PARASITE TRANSMISSION; PARASITEMIA; PERUVIAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; BLOOD; GENETICS; IMMUNOLOGY; MIDDLE AGED; PARASITOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; FEMALE; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; YOUNG ADULT;

EID: 84926639432     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu614     Document Type: Conference Paper

References (43)

1. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
2. Crompton PD, Moebius J, Portugal S, et al. Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. Ann Rev Immunol 2014; 32:157-87.
3. Sergent E, Parrot L. Premunition in bovine piroplasmosis and human malaria. Ann Trop Med Parasitol 1950; 44:329-30.
4. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci USA 2010; 107: 6958-63.
5. Baird JK, Jones TR, Danudirgo EW, et al. Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am J Trop Med Hyg 1991; 45:65-76.
6. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 2002; 66:641-8.
7. Vinetz JM, Gilman RH. Asymptomatic Plasmodium parasitemia and the ecology of malaria transmission. Am J Trop Med Hyg 2002; 66:639-40.
8. Roshanravan B, Kari E, Gilman RH, et al. Endemic malaria in the Peruvian Amazon region of Iquitos. Am J Trop Med Hyg 2003; 69: 45-52.
9. Branch O, Casapia WM, Gamboa DV, et al. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Malar J 2005; 4:27.
10. Chuquiyauri R, Paredes M, Penataro P, et al. Socio-demographics and the development of malaria elimination strategies in the low transmission setting. Acta Trop 2012; 121:292-302.
11. da Silva-Nunes M, Moreno M, Conn JE, et al. Amazonian malaria: Asymptomatic human reservoirs, diagnostic challenges, environmentally driven changes in mosquito vector populations, and the mandate for sustainable control strategies. Acta Trop 2012; 121:281-91.
12. Camargo EP, Alves F, Pereira da Silva LH. Symptomless Plasmodium vivax infections in native Amazonians. Lancet 1999; 353:1415-6.
13. Alves FP, Gil LH, Marrelli MT, Ribolla PE, Camargo EP, Da Silva LH. Asymptomatic carriers of Plasmodium spp. as infection source for malaria vector mosquitoes in the Brazilian Amazon. J Med Entomol 2005; 42:777-9.
14. Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003; 37:1659-67.
15. Clark EH, Silva CJ, Weiss GE, et al. Plasmodium falciparum malaria in the Peruvian Amazon, a region of low transmission, is associated with immunologic memory. Infect Immun 2012; 80:1583-92.
16. McGregor IA. Mechanisms of acquired immunity and epidemiological patterns of antibody responses in malaria in man. Bull WHO 1974; 50:259-66.
17. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: More questions than answers. Nat Immunol 2008; 9:725-32.
18. Mangold KA, Manson RU, Koay ES, et al. Real-time PCR for detection and identification of Plasmodium spp. J Clin Microbiol 2005; 43:2435-40.
19. Doolan DL, Aguiar JC, Weiss WR, et al. Utilization of genomic sequence information to develop malaria vaccines. J Exp Biol 2003; 206: 3789-802.
20. Riehle MA, Srinivasan P, Moreira CK, Jacobs-Lorena M. Towards genetic manipulation of wild mosquito populations to combat malaria: advances and challenges. J Exp Biol 2003; 206:3809-16.
21. Trieu A, Kayala MA, Burk C, et al. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics 2011; 10:M111.007948.
22. Baldi P, Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 2001; 17:509-19.
23. Diez-Silva M, Park Y, Huang S, et al. Pf155/RESA protein influences the dynamic microcirculatory behavior of ring-stage Plasmodium falcipa-rum infected red blood cells. Sci Rep; 2:614.
24. Silva MD, Cooke BM, Guillotte M, et al. A role for the Plasmodium falciparum RESA protein in resistance against heat shock demonstrated using gene disruption. Mol Microbiol 2005; 56:990-1003.
25. Sinha A, Hughes KR, Modrzynska KK, et al. A cascade of DNA-binding proteins for sexual commitment and development in Plasmodium. Nature 2014; 507:253-7.
26. Park DJ, Lukens AK, Neafsey DE, et al. Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite. Proc Natl Acad Sci USA 2012; 109: 13052-7.
27. Doolan DL, Mu Y, Unal B, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008; 8:4680-94.
28. Rotman HL, Daly TM, Long CA. Plasmodium: immunization with car-boxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Exp Parasitol 1999; 91: 78-85.
29. Keitel WA, Kester KE, Atmar RL, et al. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epi-topes of tetanus toxoid. Vaccine 1999; 18:531-9.
30. Chenet SM, Branch OH, Escalante AA, Lucas CM, Bacon DJ. Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru. Malar J 2008; 7:93.
31. Barry AE, Trieu A, Fowkes FJ, et al. The stability and complexity of antibody responses to the major surface antigen of Plasmodium falcip-arum are associated with age in a malaria endemic area. Mol Cell Pro-teomics 2011; 10:M111.008326.
32. Beshir KB, Sutherland CJ, Sawa P, et al. Residual Plasmodium falcipa-rum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis 2013; 208:2017-24.
33. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011; 24:377-410.
34. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013; 207:1637-45.
35. Sundaresh S, Doolan DL, Hirst S, et al. Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques. Bioinformatics 2006; 22:1760-6.
36. Pacheco MA, Elango AP, Rahman AA, Fisher D, Barnwell JW, Escalante AA. Evidence of purifying selection on merozoite surface protein 8 (MSP8) and 10 (MSP10) in Plasmodium spp. Infect Genet Evol 2012; 12:978-86.
37. Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 1991; 174:1203-8.
38. Kaslow DC, Quakyi IA, Syin C, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988; 333:74-6.
39. Williamson KC. Pfs230: from malaria transmission-blocking vaccine candidate toward function. Parasite Immunol 2003; 25:351-9.
40. van Dijk MR, Janse CJ, Thompson J, et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell 2001; 104:153-64.
41. Drew DR, Sanders PR, Crabb BS. Plasmodium falciparum merozoite surface protein 8 is a ring-stage membrane protein that localizes to the parasitophorous vacuole of infected erythrocytes. Infect Immun 2005; 73:3912-22.
42. Torres KJ, Clark EH, Hernandez JN, Soto-Cornejo KE, Gamboa D, Branch OH. Antibody response dynamics to the Plasmodium falcipa-rum conserved vaccine candidate antigen, merozoite surface protein-1 C-terminal 19kD (MSP1-19kD), in Peruvians exposed to hypoendemic malaria transmission. Malar J 2008; 7:173.
43. Villasis E, Lopez-Perez M, Torres K, et al. Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru. Malar J 2012; 11:361.